Fig. 3

Approaches for targeting each CNS disease. a Nanomedicines functionalized with ligands targeting receptors expressed on GBMs. The oleic acid capped manganese oxide (MnO) oxide nanoparticles were decorated with folic acid, a glioma-specific moiety. MRI images of brains bearing C6 tumors, receiving i MnO NPs decorated with N-(trimethoxysilylpropyl) ethylene diamine triacetic acid (TETT) silane or ii MnO NPs decorated with both TETT and folic acid via post intravenous injection for 2 h, confirmed the deposition of targeted nanoparticles in the small tumor region. Reproduced with permission [115]. Copyright 2014, American Chemical Society Publications. b Aβ-targeted nanomedicines for AD diagnosis. MRI images show that i Gadolinium (Gd)-based nanoparticles decorated with Aβ-targeting peptides were accumulated around Aβ plaques in the AD mouse brain while ii bare Gd nanoparticles were not able to detect Aβ plaques. Scale bars represent 50 µm. Reproduced with permission [141]. Copyright 2016, Springer Nature. c Nanomedicines targeting PD. i Schematic configuration of PD-targeted nanoparticles. The conjugation of RVG29 to nanoparticles (RNP-cy5.5) achieved, ii the significantly enhanced in vitro BBB permeability and the iii, iv effective delivery to in vivo PD brain region compared to bare nanoparticles. Reproduced with permission [148]. Copyright 2018, American Chemical Society Publications